Ascendis Pharma A/S (NASDAQ:ASND) management will conduct a conference call for 11th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.ascendispharma.com
Earnings Expectation
Ascendis Pharma A/S clinical stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Wednesday 11th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.88 per share from revenue of $ 1.66 million. Looking ahead, the full year loss are expected at $ 7.61 per share on the revenues of $ 8.67 million.
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies.
